← Back to Search

Chemotherapy

TACE + SBRT for Liver Cancer

N/A
Waitlist Available
Led By Tarita Thomas, MD, PhD
Research Sponsored by Abramson Cancer Center of the University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age > 18 years old
Meets clinical criteria for eligibility for TACE to the target lesion per Interventional Radiology
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 10 days
Awards & highlights

Study Summary

This trial will study whether combining two cancer treatments, SBRT and TACE, is effective for patients with HCC awaiting liver transplantation.

Who is the study for?
This trial is for adults over 18 with hepatocellular carcinoma who are on or recommended for a liver transplant list. They should be able to undergo TACE, have Childs' Class A or B7 liver function, and an ECOG performance status of 0 or 1. Pregnant women, those in other treatment studies, with certain medical conditions like active GI ulcers or bleeds, prior upper abdomen radiotherapy or liver treatments are excluded.Check my eligibility
What is being tested?
The study is testing if combining two treatments—TACE and SBRT—is effective as a temporary solution (bridging therapy) for patients with liver cancer waiting for a transplant. It's the first study of its kind and aims to enroll 40 patients into each treatment group.See study design
What are the potential side effects?
Possible side effects from TACE may include abdominal pain, fever, nausea; while SBRT could cause fatigue, skin reactions at the treatment site, and gastrointestinal symptoms.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am older than 18 years.
Select...
I am eligible for a specific liver cancer treatment as per my radiologist.
Select...
I am able to understand and agree to the study's procedures and risks.
Select...
I have liver cancer and am on or recommended for the liver transplant list.
Select...
I am fully active or restricted in physically strenuous activity but can do light work.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~10 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 10 days for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Progression Free Survival

Trial Design

2Treatment groups
Experimental Treatment
Group I: B - Tace combined with SBRTExperimental Treatment2 Interventions
B- TACE combined with SBRT (experimental group).
Group II: A -Tace aloneExperimental Treatment1 Intervention
A - TACE alone (control group, current practice and treatment)

Find a Location

Who is running the clinical trial?

Abramson Cancer Center of the University of PennsylvaniaLead Sponsor
359 Previous Clinical Trials
105,101 Total Patients Enrolled
1 Trials studying Liver Cancer
18 Patients Enrolled for Liver Cancer
Abramson Cancer Center at Penn MedicineLead Sponsor
383 Previous Clinical Trials
144,857 Total Patients Enrolled
1 Trials studying Liver Cancer
18 Patients Enrolled for Liver Cancer
Loyola UniversityOTHER
156 Previous Clinical Trials
31,382 Total Patients Enrolled

Media Library

Transarterial Chemoembolization (TACE) (Chemotherapy) Clinical Trial Eligibility Overview. Trial Name: NCT01918683 — N/A
Liver Cancer Research Study Groups: A -Tace alone, B - Tace combined with SBRT
Liver Cancer Clinical Trial 2023: Transarterial Chemoembolization (TACE) Highlights & Side Effects. Trial Name: NCT01918683 — N/A
Transarterial Chemoembolization (TACE) (Chemotherapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01918683 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still slots available for participants in this investigation?

"This study, which was posted on July 1st 2013 and officially updated December 3rd 2021 is no longer open to applicants. Nonetheless, there are many other clinical trials that remain actively recruiting patients at this time with a total of 2609 studies available for participation."

Answered by AI
~8 spots leftby Dec 2026